EMILY YODER: Open Payments
NPI 1164106084 · ALEXANDRIA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,861 in 106 payments from 20 companies in 2025. Trend: 2023 $147 · 2024 $627 · 2025 $1,861
Food & beverage: $1,861
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $364 |
| AstraZeneca Pharmaceuticals LP | 16 | $341 |
| Novo Nordisk Inc | 13 | $222 |
| Otsuka America Pharmaceutical, Inc. | 8 | $151 |
| Lilly USA, LLC | 9 | $127 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $78 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
| Kowa Pharmaceuticals America, Inc. | 4 | $61 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $58 |
| Exact Sciences Corporation | 3 | $57 |
Products named: QULIPTA, REXULTI, FARXIGA, JARDIANCE, MOUNJARO, VRAYLAR, Ozempic, UBRELVY.
Industry payments across LA — which companies pay providers there.
